Transgene to Participate in HTID Conference and Investor Access Forum in Paris
05 September 2024 - 5:45PM
Strasbourg, France, September
5, 2024, 5 : 45 PM CET – Transgene (Euronext
Paris: TNG), a biotech company that designs and develops
virus-based immunotherapies for the treatment of cancer, announces
that its management will participate in the following
upcoming investor meetings taking place in Paris,
France:
- 6th HealthTech Innovation Days (HTID), September 17
& 18, 2024
- Investor Access Forum, October 15 & 16,
2024
***
About Transgene
Transgene (Euronext: TNG) is a biotechnology
company focused on designing and developing targeted
immunotherapies for the treatment of cancer. Transgene’s programs
utilize viral vector technology with the goal of indirectly or
directly killing cancer cells. The Company’s clinical-stage
programs consist of a portfolio of therapeutic vaccines and
oncolytic viruses: TG4050, the first individualized therapeutic
vaccine based on the myvac® platform, TG4001 for the treatment of
HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic
viruses based on the Invir.IO® viral backbone. With Transgene’s
myvac® platform, therapeutic vaccination enters the field of
precision medicine with a novel immunotherapy that is fully
tailored to each individual. The myvac® approach allows the
generation of a virus-based immunotherapy that encodes
patient-specific mutations identified and selected by Artificial
Intelligence capabilities provided by its partner NEC. With its
proprietary platform Invir.IO®, Transgene is building on its viral
vector engineering expertise to design a new generation of
multifunctional oncolytic viruses. Additional information about
Transgene is available at: www.transgene.frFollow us on social
media: X (previously-Twitter): @Transgene - LinkedIn:
@Transgene
Contacts
Transgene Contact:
Transgene
Media Contact:Media:
MEDiSTRAVACaroline Tosch
Frazer Hall/Sylvie
BerrebiCorporate Communication Manager
+ 44
(0)203 928 6900+33 (0)3 68 33 27 38
transgene@medistrava.comcommunication@transgene.fr
Lucie
Larguier
Chief Financial
Officer
Nadege
Bartoli
IR Analyst and Financial Communications
Officer
+33 (0)3 88 27 91 03
/00
investorrelations@transgene.fr
Transgene disclaimer
This press release contains forward-looking
statements, which are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
anticipated. The occurrence of any of these risks could have a
significant negative outcome for the Company’s activities,
perspectives, financial situation, results, regulatory authorities’
agreement with development phases, and development. The Company’s
ability to commercialize its products depends on but is not limited
to the following factors: positive pre-clinical data may not be
predictive of human clinical results, the success of clinical
studies, the ability to obtain financing and/or partnerships for
product manufacturing, development and commercialization, and
marketing approval by government regulatory authorities. For a
discussion of risks and uncertainties which could cause the
Company’s actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque”)
section of the Universal Registration Document, available on the
AMF website (http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made, and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
- 20240905_Transgene-Upcoming-Investor-Events_EN
Transgene (EU:TNG)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Transgene (EU:TNG)
Historical Stock Chart
Von Jan 2024 bis Jan 2025
